Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines
AlphaTON Capital (Nasdaq: ATON) and subsidiary Cyncado Therapeutics reported preclinical results showing that co‑administration of selective adenosine A2B antagonist TT-4 and A2A antagonist TT-10 with antigen-specific cancer vaccines produced strong antitumor effects in three mouse models.
The triple combination (TT-4 + TT-10 + vaccine) significantly suppressed tumor growth, improved survival, elicited intratumoral CD8+ T-cell responses, produced complete tumor regressions in several mice, and conferred resistance to tumor rechallenge. Data were presented at SITC on November 8, 2025. Clinical status: TT-10 is in Phase 1 dose escalation and TT-4 is IND-enabled and preparing for first‑patient dosing in Q1 2026.
AlphaTON Capital (Nasdaq: ATON) e la sua controllata Cyncado Therapeutics hanno riportato risultati preclinici che mostrano che la co-somministrazione di antagonista selettivo dell'adenosina A2B TT-4 e antagonista A2A TT-10 con vaccini antitumore specifici per l'antigene hanno prodotto forti effetti antitumorali in tre modelli murini.
La triple combinazione (TT-4 + TT-10 + vaccino) ha significativamente modulato la crescita tumorale, migliorato la sopravvivenza, generato risposte di CD8+ T intratumorali, prodotto regressioni tumorali complete in diversi topi e conferito resistenza a una rilancia del tumore. I dati sono stati presentati al SITC il 8 novembre 2025. Stato clinico: TT-10 è in fase di escalation della dose nella Fase 1 e TT-4 è abilitato IND e si sta preparando per la somministrazione al primo paziente nel Q1 2026.
AlphaTON Capital (Nasdaq: ATON) y la empresa subsidiaria Cyncado Therapeutics reportaron resultados preclínicos que muestran que la coadministración del antagonista selectivo de adenosina A2B TT-4 y del antagonista A2A TT-10 con vacunas contra el cáncer específicas del antígeno produjo potentes efectos antitumorales en tres modelos murinos.
La combinación triple (TT-4 + TT-10 + vacuna) suprimió significativamente el crecimiento tumoral, mejoró la supervivencia, provocó respuestas de células CD8+ intratumorales, produjo regresiones tumorales completas en varios ratones y confirió resistencia a un nuevo reto tumoral. Los datos se presentaron en SITC el 8 de noviembre de 2025. Estado clínico: TT-10 está en fase 1 de escalamiento de dosis y TT-4 está IND-enabled y se está preparando para la dosificación del primer paciente en el primer trimestre de 2026.
AlphaTON Capital (나스닥: ATON)과 자회사 Cyncado Therapeutics는 선택적 아데노신 A2B 길항제 TT-4와 A2A 길항제 TT-10를 항원 특이적 암 백신과 함께 병용 투여했을 때 세 가지 마우스 모델에서 강력한 항종양 효과를 보였다는 전임상 결과를 보고했습니다.
삼중 조합(TT-4 + TT-10 + 백신)은 종양 성장에 관여하는 효과를 크게 억제하고 생존을 향상시키며 종양 내 CD8+ T세포 반응을 유발했고, 여러 마우스에서 종양 완전 회복을 초래했으며 종양 재도전에 대한 저항성을 부여했습니다. 데이터는 SITC에서 2025년 11월 8일에 발표되었습니다. 임상 상태: TT-10은 용량 증량 1상에 있으며 TT-4은 IND 활성화 상태로 2026년 1분기에 첫 환자 투여를 준비 중입니다.
AlphaTON Capital (au Nasdaq : ATON) et sa filiale Cyncado Therapeutics ont présenté des résultats précliniques montrant que la co-administration de l’antagoniste sélectif de l’adénosine A2B TT-4 et de l’antagoniste A2A TT-10 avec des vaccins anticancéreux spécifiques à l’antigène produit des effets antitumoraux forts dans trois modèles murins.
La triple combinaison (TT-4 + TT-10 + vaccin) a significativement suppressé la croissance tumorale, amélioré la survie, provoqué des réponses de lymphocytes T CD8+ intratumoraux, entraîné des régressions tumorales complètes chez plusieurs souris et conféré une résistance à une rechallenge tumorale. Les données ont été présentées au SITC le 8 novembre 2025. Statut clinique : TT-10 est en escalade de dose en phase 1 et TT-4 est IND-enabled et se prépare pour l'administration au premier patient au 1er trimestre 2026.
AlphaTON Capital (Nasdaq: ATON) und die Tochtergesellschaft Cyncado Therapeutics berichteten von präklinischen Ergebnissen, die zeigen, dass die gleichzeitige Verabreichung des selektiven Adenosin A2B-Antagonisten TT-4 und des A2A-Antagonisten TT-10 zusammen mit antigen-spezifischen Krebsimpfstoffen starke antitumorale Effekte in drei Mausmodellen hervorrief.
Die Dreifachkombination (TT-4 + TT-10 + Impfung) unterdrückte das Tumorwachstum signifikant, verbesserte das Überleben, löste intratumorale CD8+ T-Zell-Reaktionen aus, führte bei mehreren Mäusen zu vollständigen Tumorregressionen und verlieh eine Resistenz gegen eine erneute Tumorherausforderung. Die Daten wurden auf dem SITC am 8. November 2025 vorgestellt. Klinischer Status: TT-10 befindet sich in einer Phasen-1-Dosis-Eskalation und TT-4 ist IND-fähig und bereitet die Verabreichung beim ersten Patienten im Q1 2026 vor.
AlphaTON Capital (Nasdaq: ATON) وشركتها التابعة Cyncado Therapeutics أبلغتا عن نتائج ما قبل السريرية تُظهر أن الإدارة المشتركة لمثبط اختياري للأدينوسين A2B TT-4 ومثبط A2A TT-10 مع لقاحات سرطان محددة للمستضد أنتجت تأثيرات مضادة للورم قوية في ثلاث نماذج فئران.
التركيبة الثلاثية (TT-4 + TT-10 + اللقاح) خفّضت نمو الورم بشكل كبير، حسّنت البقاء على قيد الحياة، أثارت استجابات CD8+ T داخل الورم، أدت إلى انخفاض الورم بالكامل في عدة فئران ومنحت مقاومة لإعادة تحدي الورم. تم عرض البيانات في SITC في 8 نوفمبر 2025. الوضع السريري: TT-10 في مرحلة تصعيد الجرعة من المرحلة 1 وTT-4 متاح بموجب IND ويجري التحضير لإعطاء الجرعة لأول مريض في الربع الأول من 2026.
- Complete tumor regressions observed in several mice
- Triple combo suppressed tumor growth and improved survival
- Intratumoral CD8+ T-cell responses elicited by the combination
- Therapeutic synergy confirmed in three mouse cancer models
- TT-4 is IND-enabled and preparing first‑patient dosing Q1 2026
- TT-10 Phase 1 dose escalation is ongoing
- Evidence limited to preclinical mouse models
- No human clinical efficacy data reported yet
Insights
Robust preclinical synergy reported: dual A2B/A2A antagonists plus vaccines produced tumor regressions and rechallenge resistance in mice.
Investigators at the National Cancer Institute evaluated co‑administration of a selective A2B antagonist (TT‑4) and a selective A2A antagonist (TT‑10) together with antigen‑specific cancer vaccines across three mouse models (TC1, CT26, B16F10). The triple regimen produced significant tumor growth suppression, improved survival, intratumoral CD8+ T‑cell responses, and several complete regressions that resisted tumor rechallenge without checkpoint inhibitors.
These data strengthen the biological rationale for combining adenosine pathway blockade with vaccines. Key dependencies include clinical translation of the immunologic effects seen in mice and tolerability in humans. Concrete near‑term items to watch are completion of TT‑10 dose escalation in advanced solid tumors, preparation for first‑patient dosing for TT‑4 in mesothelioma in
Data from studies conducted by investigators at the National Cancer Institute at NCI laboratories, part of a multi-year research effort, will be presented at SITC
Dover, DE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (“Cyncado”), today announced a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 5 to 9, 2025, in National Harbor, Maryland. The poster reports preclinical findings from work conducted by investigators at the National Cancer Institute (NCI) at NCI laboratories. In these studies, NCI researchers evaluated combinations of selective adenosine A2B antagonism (TT-4) and A2A antagonism (TT-10) with antigen-specific cancer vaccines.
Experiments in three therapeutic cancer vaccine mouse models, conducted by investigators at the Vaccine Branch of the National Cancer Institute in Bethesda, Maryland, support the conclusion that strategies optimized to inhibit both adenosine A2B and A2A receptor mediated immune suppression can synergize with therapeutic tumor-specific vaccines to provide a robust antitumor immune response that should be translatable to humans. Synergy was observed in the TC1 lung cancer model using a triple combination of co-administered TT-4, a selective A2B receptor antagonist and TT-10, a selective A2A receptor antagonist, together with an E7 peptide therapeutic vaccine. This triple combination significantly suppressed tumor growth, improved survival, and elicited specific intratumoral CD8+ T-cell responses. Notably, several mice receiving this combination displayed complete tumor regression and resisted tumor rechallenge without the addition of checkpoint inhibitors. Therapeutic synergy was confirmed in two additional murine models: the CT26 colon cancer model using irradiated CT26 cells as a whole-cell vaccine and the poorly immunogenic B16F10 melanoma model administered a gp100 peptide based vaccine.
“This collaboration with NCI investigators reflects a multi-year effort to define how co-administration of selective A2B and A2A receptor antagonists can amplify vaccine-driven immunity,” said Robert Kramer, PhD, Chief Scientific Officer of Cyncado Therapeutics. “Dose escalation for TT-10 in patients with solid tumors is nearing completion, and we are preparing TT-4 for first-patient dosing as part of our planned mesothelioma trial, with the goal of prioritizing indications where these investigational drugs can have the greatest impact.”
“At AlphaTON, one of our strategic goals is to pair disciplined digital infrastructure with rigorous life science programs,” said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. “These preclinical data strengthen our thesis on adenosine biology and guide how we deploy capital and partnerships to advance TT-4 and TT-10 in the clinic.”
Clinical program status
- TT-4 (A2BR antagonist): IND-enabled program, with mesothelioma as the lead indication, preparing for first-patient dosing in Q1 2026 under the company’s existing protocol framework
- TT-10 (A2AR antagonist): Phase 1 dose escalation is ongoing in advanced solid tumors
SITC poster details
- Title: Cancer vaccines synergize with adenosine inhibitors to improve survival and delay tumor progression in lung, colon, and melanoma cancer models in vivo
- Session: Poster Hall
- Abstract number: 662
- Date and time: Saturday, November 8, 2025
Acknowledgments and disclaimers related to NCI
This work was conducted by investigators at the National Cancer Institute at NCI laboratories as part of a multi-year Cooperative Research and Development Agreement # 03442. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Cancer Institute. Mention of any commercial products does not imply endorsement by the United States Government.
About AlphaTON Capital Corp
AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The Company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company.
Led by Chief Executive Officer Brittany Kaiser and Chief Investment Officer, Enzo Villani, the company's activities span network validation and staking operations, development of Telegram-based applications, and strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications. AlphaTON Capital Corp is headquartered in the British Virgin Islands and trades on Nasdaq under the symbol ATON.
AlphaTON Capital, through its legacy business, is also advancing first-in-class therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide development of novel immunotherapy assets and asset combinations.
About Cyncado Therapeutics
Tarus Therapeutics, LLC (operating as Cyncado Therapeutics), a clinical stage, wholly owned subsidiary of AlphaTON Capital Corp, is developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2B and A2A receptors to overcome immune suppression in oncology. The Company's lead program, TT-4, is an oral, ultra-selective A2B receptor antagonist with an initial focus on mesothelioma, advancing toward first-patient dosing in Q1 2026. Cyncado is also developing dual-antagonist strategies designed to achieve comprehensive blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company's business strategy, plans and objectives, future operations, exploration of tokenization frameworks, clinical development timelines, potential decentralized science (DeSci) applications, TON ecosystem growth, therapeutic development outcomes, regulatory approvals, financing activities, and statements preceded by, followed by, or including words such as "believe," "expects," "anticipates," "intends," "estimates," "will," "may," "plans," "potential," "targets," or similar expressions, are forward-looking statements.
These forward-looking statements are subject to substantial risks and uncertainties, including but not limited to: risks that tokenization or DeSci frameworks may not be pursued or successfully implemented; uncertainty regarding the Company’s and Cyncado’s ability to enter into definitive agreements on reasonable terms; uncertainty regarding clinical trial outcomes and regulatory approvals; uncertainty of the Company's investment in TON and digital assets; regulatory and legal risks associated with digital assets and tokenization; risks related to Telegram's platform and the TON ecosystem; market volatility; competitive risks in both digital assets and therapeutics development; ability to attract and retain key personnel; the Company’s ability to satisfy its debt service obligations and covenant compliance; macroeconomic conditions; and other factors described in "Item 3 – Key Information-Risk Factors" in the Company's Annual Report on Form 20-F for the year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.
Although the Company believes the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to update publicly or revise any forward-looking statements, except as required by law.
Contact Information
Investor Relations
AlphaTON Capital Corp
AlphaTON@icrinc.com
(203) 682-8200
Media Inquiries
Richard Laermer
RLM PR
AlphaTON@rlmpr.com
(212) 741-5106 X 216
Richard Laermer AlphaTON (at) rlmpr.com
FAQ
What did AlphaTON (ATON) report at SITC on November 8, 2025?
Which cancer models showed therapeutic synergy with TT-4 and TT-10 in the ATON poster?
What is the clinical status of Cyncado’s TT-4 and TT-10 (ATON)?
Did mice that received the TT-4/TT-10/vaccine combination show durable responses?
Where and when was the Cyncado poster presented at SITC 2025?
